JP7846627B2 - 新規な免疫活性インターロイキン２アナログ - Google Patents

新規な免疫活性インターロイキン２アナログ

Info

Publication number
JP7846627B2
JP7846627B2 JP2022559531A JP2022559531A JP7846627B2 JP 7846627 B2 JP7846627 B2 JP 7846627B2 JP 2022559531 A JP2022559531 A JP 2022559531A JP 2022559531 A JP2022559531 A JP 2022559531A JP 7846627 B2 JP7846627 B2 JP 7846627B2
Authority
JP
Japan
Prior art keywords
interleukin
amino acids
amino acid
deleted
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515247A (ja
Inventor
ウ リム オ
サン ユン キム
ヨン ホ ホ
ジン ヨン キム
チョ ロン パク
ジュン ソプ パク
ヒュン ス リュ
Original Assignee
ハンミ ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンミ ファーマシューティカル カンパニー リミテッド filed Critical ハンミ ファーマシューティカル カンパニー リミテッド
Publication of JP2023515247A publication Critical patent/JP2023515247A/ja
Priority to JP2023202447A priority Critical patent/JP2024041747A/ja
Application granted granted Critical
Publication of JP7846627B2 publication Critical patent/JP7846627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022559531A 2020-03-31 2021-03-31 新規な免疫活性インターロイキン２アナログ Active JP7846627B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023202447A JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン２アナログ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200039476 2020-03-31
KR10-2020-0039476 2020-03-31
PCT/KR2021/004028 WO2021201615A1 (ko) 2020-03-31 2021-03-31 신규한 면역 활성 인터루킨 2 아날로그

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023202447A Division JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン２アナログ

Publications (2)

Publication Number Publication Date
JP2023515247A JP2023515247A (ja) 2023-04-12
JP7846627B2 true JP7846627B2 (ja) 2026-04-15

Family

ID=77930406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559531A Active JP7846627B2 (ja) 2020-03-31 2021-03-31 新規な免疫活性インターロイキン２アナログ
JP2023202447A Pending JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン２アナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023202447A Pending JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン２アナログ

Country Status (17)

Country Link
US (2) US11746137B2 (https=)
EP (1) EP4130027A4 (https=)
JP (2) JP7846627B2 (https=)
KR (2) KR102545250B1 (https=)
CN (2) CN118271419A (https=)
AR (1) AR121713A1 (https=)
AU (2) AU2021202825B2 (https=)
BR (1) BR112022018730A2 (https=)
CA (2) CA3266069A1 (https=)
CL (1) CL2022002562A1 (https=)
IL (1) IL295826B2 (https=)
MX (1) MX2022011893A (https=)
NZ (1) NZ793819A (https=)
PE (1) PE20221759A1 (https=)
TW (1) TWI876021B (https=)
WO (1) WO2021201615A1 (https=)
ZA (1) ZA202209565B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
KR102445492B1 (ko) * 2021-12-24 2022-09-21 엔케이젠 주식회사 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법
US20240076343A1 (en) * 2022-06-16 2024-03-07 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
JP2025527694A (ja) * 2022-08-23 2025-08-22 マストバイオ株式会社 Ｉｌ２変異体及びそれを含むタンパク質複合体
KR20250126198A (ko) 2024-02-15 2025-08-25 한림대학교 산학협력단 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502967A (ja) 2010-12-22 2014-02-06 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ インターロイキン２のスーパーアゴニストおよびアンタゴニスト
JP2016533167A (ja) 2013-09-24 2016-10-27 メディシナ セラピューティクス ピーティーイー リミテッド インターロイキン−２融合タンパク質及びその使用
JP2017518361A (ja) 2014-04-24 2017-07-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3285989A (en) * 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
AU627477B2 (en) * 1988-07-05 1992-08-27 Amgen, Inc. Interleukin ii analogs
CA2019714A1 (en) 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20060234205A1 (en) 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
CN1930300A (zh) 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
AU2007201663A1 (en) 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
DK2963056T3 (da) 2013-02-26 2020-02-17 Hanmi Pharm Ind Co Ltd Insulinanalog og anvendelse deraf
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acción prolongada y uso de la misma
JP6821560B2 (ja) 2014-10-21 2021-01-27 サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． 免疫刺激剤による癌治療
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
KR20160134989A (ko) * 2015-05-14 2016-11-24 순천향대학교 산학협력단 인간 인터류킨-2 단백질을 포함하는 약학조성물
CN107266553A (zh) * 2016-04-08 2017-10-20 南京康志制药有限公司 高效人白细胞介素ⅱ突变体融合蛋白及其应用
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
CA3055200A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
CN111094356B (zh) * 2017-09-25 2022-11-01 苏州丁孚靶点生物技术有限公司 一种蛋白质异二聚体及其用途
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2019147837A2 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
CN108503714A (zh) 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
AU2019271148B9 (en) * 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
KR20250156190A (ko) * 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.
US11492384B2 (en) * 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
CN113316590B (zh) * 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114437198A (zh) 2019-12-17 2022-05-06 北京志道生物科技有限公司 白介素-2衍生物
CA3169095A1 (en) 2020-03-05 2021-09-10 Kenan Christopher GARCIA Designed il-2 variants
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502967A (ja) 2010-12-22 2014-02-06 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ インターロイキン２のスーパーアゴニストおよびアンタゴニスト
JP2016533167A (ja) 2013-09-24 2016-10-27 メディシナ セラピューティクス ピーティーイー リミテッド インターロイキン−２融合タンパク質及びその使用
JP2017518361A (ja) 2014-04-24 2017-07-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof

Also Published As

Publication number Publication date
US11746137B2 (en) 2023-09-05
KR20230088656A (ko) 2023-06-20
CN115427437A (zh) 2022-12-02
AU2021202825A1 (en) 2021-10-14
US20230124171A1 (en) 2023-04-20
AU2021202825B2 (en) 2022-06-30
CA3169564A1 (en) 2021-10-07
EP4130027A1 (en) 2023-02-08
BR112022018730A2 (pt) 2022-11-01
CA3266069A1 (en) 2026-03-02
CA3169564C (en) 2025-05-06
IL295826B2 (en) 2025-11-01
WO2021201615A1 (ko) 2021-10-07
CL2022002562A1 (es) 2023-03-17
TWI876021B (zh) 2025-03-11
KR102946368B1 (ko) 2026-04-01
CN118271419A (zh) 2024-07-02
ZA202209565B (en) 2023-12-20
EP4130027A4 (en) 2024-08-14
JP2023515247A (ja) 2023-04-12
AR121713A1 (es) 2022-06-29
NZ793819A (en) 2026-03-27
MX2022011893A (es) 2022-10-18
KR20210122200A (ko) 2021-10-08
IL295826A (en) 2022-10-01
US20230348550A1 (en) 2023-11-02
KR102545250B1 (ko) 2023-06-21
CN115427437B (zh) 2024-04-19
IL295826B1 (en) 2025-07-01
AU2022203841A1 (en) 2022-06-23
US12415842B2 (en) 2025-09-16
JP2024041747A (ja) 2024-03-27
PE20221759A1 (es) 2022-11-11
TW202204387A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
JP7846627B2 (ja) 新規な免疫活性インターロイキン２アナログ
US20220025007A1 (en) Novel immunosuppressive interleukin 2
CN112552391B (zh) 一种重组白介素-15类似物
CA3205058C (en) Conjugate of immune-stimulating il-2 analog and preparation method thereof
RU2843530C1 (ru) Новые иммуностимулирующие аналоги интерлейкина-2
HK40079776A (en) Novel immunoactive interleukin 2 analog
KR20230095612A (ko) 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
TWI922649B (zh) 免疫刺激il-2類似物的新穎接合物及其製備方法
HK40100172A (en) Novel immunoactive interleukin 2 analog conjugate and method for preparing same
WO2024046280A1 (zh) 一种聚乙二醇修饰的il-21衍生物及其应用
EA049515B1 (ru) Новый конъюгат иммуностимулирующего аналога интерлейкина-2 и способ его получения
JP2026509259A (ja) インターロイキン２アナログ又はその結合体を含む癌予防又は治療用薬学的組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220929

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231206

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260403

R150 Certificate of patent or registration of utility model

Ref document number: 7846627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150